Emerging Alzheimer's disease treatment paradigms: A late‐stage clinical trial review
An analysis of Alzheimer's disease trial treatment paradigms was conducted.From April 2021 to March 2023, 175 trials of 123 unique candidates were reviewed.Biologic and small molecule drugs comprised 30% and 54% of trials, respectively.Eligibility criteria favored ages 60 through 80 with mild cognitive impairment.
Authors
- Jakub Hlávka (ORCID: https://orcid.org/0000-0002-2766-390X)
- Mireille Jacobson (ORCID: https://orcid.org/0000-0002-4977-8783)
- Andrew T. Kinoshita (ORCID: https://orcid.org/0000-0001-6321-3642)
- Divya Jeyasingh (ORCID: https://orcid.org/0000-0003-3894-0885)
- Leila Mirsafian
- Cheng Huang (ORCID: https://orcid.org/0000-0002-7149-9879)
Institutions
- University of Southern California (US)
- University of Arizona (US)
- University of California, Irvine (US)
- Charles University (CZ)
- Masaryk University (CZ)
Publication Details
- Journal
- Alzheimer s & Dementia Translational Research & Clinical Interventions
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/trc2.70022
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of Southern California
- Ministerstvo Školství, Mládeže a Tělovýchovy
- National Institutes of Health